|
Dec 20
|
The Zacks Analyst Blog Highlights Sarepta Therapeutics, ADMA Biologics, Exelixis and Alnylam
|
|
Dec 19
|
4 Biotech Stocks Most Wall Street Analysts Are Bullish About
|
|
Dec 19
|
Sarepta completes subject dosing in Phase III LGMD2E/R4 therapy trial
|
|
Dec 19
|
SRPT Finishes Enrolment in Late-Stage Study for Rare Muscular Disorder
|
|
Dec 18
|
Sarepta Therapeutics Completes Enrollment in EMERGENE, a Phase 3 Clinical Study of SRP-9003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2E/R4
|
|
Dec 18
|
Tessera gets sickle cell funding; Corvus shares slide on eczema data
|
|
Dec 17
|
3 Biotech Stocks With Promising Gene Therapies to Watch Out in 2025
|
|
Oct 16
|
Is Sarepta Therapeutics, Inc. (SRPT) the Most Promising Biotech Stock According to Hedge Funds?
|
|
Sep 8
|
Sarepta Therapeutics, Inc. (SRPT): This Biotech Stock Should Be On Your Radar
|
|
Sep 6
|
Why Is Sarepta Therapeutics (SRPT) Down 1.9% Since Last Earnings Report?
|
|
Sep 5
|
Sarepta Therapeutics Announces Recipients of the 7th Annual Route 79, The Duchenne Scholarship Program, for the 2024-2025 Academic Year
|
|
Aug 1
|
Sarepta Therapeutics (NASDAQ:SRPT) A Bull Case Theory
|
|
Jul 30
|
Zacks Industry Outlook Highlights Moderna, Sarepta Therapeutics, Halozyme Therapeutics, Krystal Biotech and Axsome Therapeutics
|
|
Jul 29
|
Sarepta Therapeutics Poised for 'Significant Launch Inflection' Amid Positive Elevidys Feedback, RBC Says
|
|
Jul 29
|
5 Biotech Stocks to Bet On Bright Industry Prospects
|
|
Jul 29
|
Sarepta Therapeutics to Announce Second Quarter 2024 Financial Results
|
|
Jun 27
|
Biotech Stock Roundup: ALNY Up on Study Success, ALIM on Merger News & Other Updates
|
|
Jun 26
|
Is Pfizer's Pain Sarepta Therapeutics' Gain? Don't Bet on It.
|
|
Jun 26
|
Insider Sale: EVP, General Counsel Ryan Brown Sells 38,957 Shares of Sarepta Therapeutics Inc (SRPT)
|
|
Jun 24
|
Sarepta Therapeutics Scores 90-Plus RS Rating On Muscular Dystrophy Approval
|